Eli Lilly and Company

Michael Lyle Denney

Daniel Jon Sall

Ho-Shen Lin

Richard Waltz Harper

Jolie Anne Bastian

Michael Enrico Richett

Jason Scott Sawyer

Gerald Floyd Smith

Minsheng Zhang

Kumiko Takeuchi

Jefferson Ray McCowan

Robert J Foglesong

Mary George Johnson

Nickolay Y Chirgadze

Michael P Lynch

Alan David Palkowitz

John Michael Morin, Jr

Matthew Joseph Fisher

Nicholas J Bach

Valentine Joseph Klimkowski

Jennifer Marie Tinsley

Douglas Wade Beight

Robert D Dillard

Michael LeRoy Phillips

Michael Dean Kinnick

Benjamin Alan Anderson

Susan Elizabeth Draheim

Tulio Suarez

Edward David Mihelich

Shawn Christopher Miller

Robert Theodore Vasileff

Nancy Kay Harn

Todd Jonathan Kohn

Gary A Hite

John Mcneill McGill, Iii

Richard Walter Schevitz

Richard James Loncharich

Michael Robert Wiley

Jeffrey Thomas Mullaney

John M Morin

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of conditions such as septic shock.

Substituted tricyclics

Football helmet computer case

The invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts, as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

Antithrombotic agents

This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of defined compounds of formula I as thrombin inhibitors.

Thrombin inhibitors

This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

The compound, ((3-(2-amino-1,2-dioxoethyl)-1-((1,1&prime;-biphenyl-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid N,N-diethylglycolamido ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

N,N-diethylglycolamido ester prodrugs of indole sPLA2 inhibitors

The compound, ((3(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid N-morpholino ester, is disclosed together with its use as a highly bioavailable indole sPLA,inhibitor compound.

sPLA2 inhibitor ester

This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.

Antithrombotic diamines

The compound, ((3(2-amino-1,2-dioxoethyl)-1-((1,1&prime;-biphenyl)-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid morpholino-ethyl ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

Morpholino-N-ethyl ester prodrugs of indole sPLA2 inhibitors

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

Growing community of inventors

Franklin, IN, United States of America

Michael Lyle Denney